Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

 

Patient Advocacy
Derek Naten
Vice President, Government Affairs
202-459-4143
derek.naten@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

CVC Contacts

Nick Board
CVC, Director Communications
nboard@cvc.com  

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024.

1CVC also made an irrevocable commitment to acquire the shares of the French company operating the Therakos business, Therakos (France) SAS. The definitive agreement with CVC in relation to the shares of Therakos (France) SAS will become effective after satisfaction of local information requirements.

Logo - https://mma.prnewswire.com/media/167103/4843478/mallinckrodt_plc_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mallinckrodt-reaches-agreement-to-sell-therakos-business-to-cvc-for-925-million-302214267.html

en | boerse | 67955315 |